235 related articles for article (PubMed ID: 31840521)
1. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
[TBL] [Abstract][Full Text] [Related]
2. Development and therapeutic evaluation of 5D3(CC-MLN8237)
Liatsou I; Assefa B; Liyanage W; Surasinghe S; Nováková Z; Bařinka C; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Front Pharmacol; 2024; 15():1385598. PubMed ID: 38751786
[TBL] [Abstract][Full Text] [Related]
3. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of
Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
[TBL] [Abstract][Full Text] [Related]
5. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
6. Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
Zlitni A; Yin M; Janzen N; Chatterjee S; Lisok A; Gabrielson KL; Nimmagadda S; Pomper MG; Foster FS; Valliant JF
PLoS One; 2017; 12(5):e0176958. PubMed ID: 28472168
[TBL] [Abstract][Full Text] [Related]
7. Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging.
Mandikian D; Rafidi H; Adhikari P; Venkatraman P; Nazarova L; Fung G; Figueroa I; Ferl GZ; Ulufatu S; Ho J; McCaughey C; Lau J; Yu SF; Prabhu S; Sadowsky J; Boswell CA
MAbs; 2018; 10(8):1269-1280. PubMed ID: 30199303
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
9. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
10. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
[TBL] [Abstract][Full Text] [Related]
11. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
12. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
13. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
14. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
[TBL] [Abstract][Full Text] [Related]
15.
Choy CJ; Ling X; Geruntho JJ; Beyer SK; Latoche JD; Langton-Webster B; Anderson CJ; Berkman CE
Theranostics; 2017; 7(7):1928-1939. PubMed ID: 28638478
[TBL] [Abstract][Full Text] [Related]
16. PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Owiti AO; Pal D; Mitra A
AAPS PharmSciTech; 2018 Nov; 19(8):3534-3549. PubMed ID: 30151731
[TBL] [Abstract][Full Text] [Related]
17. Diabody Pretargeting with Click Chemistry In Vivo.
van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
[TBL] [Abstract][Full Text] [Related]
18. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
[TBL] [Abstract][Full Text] [Related]
19. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
20. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.
Nedrow-Byers JR; Moore AL; Ganguly T; Hopkins MR; Fulton MD; Benny PD; Berkman CE
Prostate; 2013 Mar; 73(4):355-62. PubMed ID: 22911263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
